BioStem Technologies, Inc. (BSEM)
OTCMKTS: BSEM · Delayed Price · USD
8.85
-0.69 (-7.23%)
Jul 19, 2024, 3:59 PM EDT - Market closed
BioStem Technologies Employees
As of December 31, 1999, BioStem Technologies had 35 total employees, including 30 full-time and 5 part-time employees.
Employees
35
Change
n/a
Growth
n/a
Revenue / Employee
$1,657,529
Profits / Employee
-$15,309
Market Cap
143.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 1999 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher | 122,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
| Danaher | 63,000 |
BSEM News
- 6 days ago - BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments - Newsfile Corp
- 4 weeks ago - UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion - GlobeNewsWire
- 4 weeks ago - PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion - GlobeNewsWire
- 2 months ago - BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts - GlobeNewsWire
- 7 months ago - Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions - GlobeNewsWire
- 11 months ago - NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft - Business Wire
- 11 months ago - NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft - Business Wire
- 11 months ago - BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell - GlobeNewsWire